Warfarin-Fluconazole I - Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies

Drug Metabolism and Disposition

Volumn 24, Issue 4, 1996, Pages 414-421

  Kunze, Kent L ^a   Wienkers, Larry C ^a   Thummel, Kenneth E ^a   Trager, William F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; ENZYME INHIBITOR; FLUCONAZOLE; FURAFYLLINE; WARFARIN;

ARTICLE; CATALYSIS; DRUG HYDROXYLATION; DRUG INHIBITION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; MICHAELIS CONSTANT; PRIORITY JOURNAL;

ANTICOAGULANTS; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLUCONAZOLE; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; WARFARIN;

EID: 0029877219     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. S. M. Grant and S. P. Clissold: Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 39, 877-914 (1990).
2. C. A. Hitchcock, K. Dickinson, S. B. Brown, E. G. Evans, and D. J. Adams: Interaction of azole antifungal antibiotics with cytochrome P450-dependent 14α-sterol demethylase purified from Candida albicans. Biochem. J. 266, 475-480 (1990).
3. L. L. Crussell-Porter, J. P. Rindone, M. A. Ford, and D. W. Jaskar: Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch. Intern. Med. 153, 102-104 (1993).
4. J. D. Lazar and K. D. Wilner: Drug interactions with fluconazole. Rev. Infect. Dis.12, S327-S333 (1990).
5. J. G. Gillum, D. S. Israel, and R. E. Polk: Pharmacokinetic drug interactions with antimicrobial agents. Pharmacokinet. Drug Interact. 25, 450-482 (1993).
6. N. A. Buckley and A. H. Dawson: Drug interactions with warfarin. Med. J. Aust. 157, 479-483 (1992).
7. T. L. Seaton, C. L. Celum, and D. I. Black: Possible potentiation of warfarin by fluconazole. DICP 24, 1177-1178 (1990).
8. M. A. Touchette, P. H. Chandrasekar, M. A. Milad, and D. J. Edwards: Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br. J. Clin. Pharmacol. 34, 75-78 (1992).
9. R. A. Blum, J. H. Wilton, D. M. Hilligoss, M. J. Gardner, E. B. Henry, N. J. Harrison, and J. J. Schentag: Effect of fluconazole on the disposition of phenytoin. Clin. Pharmacol. Ther. 49, 420-425 (1991).
10. J. A. Lopez-Gil: Fluconazole-cyclosporine interaction: a dose dependent effect? Ann. Pharmacother. 27, 427-430 (1993).
11. P. K. Honig, D. C. Wortham, K. Zamani, J. C. Millin, D. P. Conner, and L. R. Cantilena: The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 53, 630-636 (1993).
12. S. Toon, L. K. Low, M. Gibaldi, W. F. Trager, R. A. O'Reilly, C. H. Motley, and D. A. Goulart: The warfarin sulfinpyrazone interaction: stereochemical considerations. Clin. Pharmacol. Ther. 39, 15-24 (1986).
13. L. D. Heimark, L. C. Wienkers, K. L. Kunze, M. Gibaldi, A. C. Eddy, W. F. Trager, R. A. O'Reilly, and D. A. Goulart: The mechanism of the interaction between amiodarone and warfarin in humans. Clin. Pharmacol. Ther. 51, 398-407 (1992).
14. R. A. O'Reilly, D. A. Goulart, K. L. Kunze, J. Neal, M. Gibaldi, A. C. Eddy, and W. F. Trager: Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin. Pharmacol Ther. 51, 656-667 (1992).
15. A. E. Rettie, A. C. Eddy, L. D. Heimark, M. Gibaldi, and W. F. Trager: Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos. 17, 265-270 (1989).
16. A. E. Rettie, K. R. Korzekwa, K. L. Kunze, R. F. Lawrence, A. C. Eddy, T. Ayoma, H. V. Gelboin, F. J. Gonzalez, and W. F. Trager: Hydroxylation of warfarin by human cDNA expressed cytochrome P450: a role for P4502C9 in the etiology of (S)-warfarin drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
17. K. L. Kunze and W. F. Trager: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656 (1993).
18. E. P. Gallagher, L. C. Wienkers, P. L. Stapleton, K. L. Kunze, and D. L. Eaton: Role of human microsomal and human complementary DNA-expressed cytochromes P450 1A2 and P450 3A4 in the bioactivation of aflatoxin B1. Cancer Res. 54, 101-108 (1994).
19. W. B. Brian, M. A. Sari, M. Iwasaki, T. Shimada, L. S. Kaminsky, and F. P. Guengerich: Catalytic activities of human liver cytochrome P450 IIIA4 expressed in saccharomyces cerevisiae. Biochemistry 29, 11280-11292 (1990).
20. L. S. Kaminsky, S. M. de Morais, M. B. Faletto, D. A. Dunbar, and J. A. Goldstein: Correlation of human cytochrome P450 2C substrate specificities with primary structure: warfarin as a probe, Mol. Pharmacol. 43, 234-239 (1993).
21. K. K. Chan, R. J. Lewis, and W. F. Trager: Absolute configuration of the four warfarin alcohols. J. Med. Chem. 15, 1265-1270 (1972).
22. T. A. Moreland and D. S. Hewick: Studies on a ketone reductase in human and rat liver and kidney soluble fraction using warfarin as a substrate. Biochem. Pharmacol. 25, 1953-1957 (1975).
23. L. D. Heimark, S. Toon, D. C. Swinney, and W. F. Trager: The synthesis of deuterium labelled metabolites of warfarin and phenprocoumon. J. Labelled Compd. Radiopharm. 23, 137-148 (1985).
24. R. F. Lawrence, A. E. Rettie, A. C. Eddy, and W. F. Trager: Chemical synthesis, absolute configuration, and stereochemistry of 10-hydroxywarfarin: a major oxidative metabolite of (+)-(R)-warfarin from hepatic microsomal preparations. Chirality 2, 96-105 (1990).
25. E. D. Kharasch and K. E. Thummel: Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? Anesth. Analg. 26, 1033-1039 (1993).
26. I. H. Segel: "Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems." John Wiley and Sons, New York, 1975.
27. K. Lavrijsen, J. Van Houdt, D. Thijs, W. Meuldermans, and J. Heykants: Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes. Xenobiotica 17, 45-57 (1987).
28. A. D. Rodrigues, D. F. V. Lewis, C. Ionannides, and D. V. Parke: Spectral and kinetic studies of the interaction of imidazole antifungal agents with microsomal cytochromes P450. Xenobiotica 17, 1315-1327 (1987).
29. A. D. Rodrigues, G. G. Gibson, C. Ionannides, and D. V. Parke: Interactions of imidazole antifungal agents with purified cytochrome P450 proteins. Biochem. Pharmacol. 36, 4277-4281 (1987).
30. K. W. Brammer, P. R. Farrow, and J. K. Faulkner Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12, S318-S326 (1990).
31. K. E. Thummel, D. D. Shen, T. D. Podoll, K. L. Kunze, W. F. Trager, P. S. Hartwell, V. A. Raisys, C. L. Marsh, J. P. McVicar, D. M. Barr, J. D. Perkins. and R. L. Carithers, Jr.: Use of midazolam as a human cytochrome P450 3A probe I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 241, 549-556 (1994).
32. K. E. Thummel, D. D. Shen, T. Podoll, K. L. Kunze, W. F. Trager, C. E. Bacchi, C. L. Marsh, J. P. McVicar, D. M. Barr, J. D. Perkins, and R. L. Carithers, Jr.: Use of midazolam as a human cytochrome P450 3A probe II. Characterization of inter- and intra-individual variability following liver transplantation. J.Pharmacol. Exp. Ther. 241, 557-566 (1994).
33. A. Breckenridge, M. Orme, H. Wessling H, R. J. Lewis, and R. Gibbons: Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther. 15, 424-430 (1974).
34. D. S. Hewick and J. McEwen: Plasma half-lives, plasma metabolites and the anticoagulant efficacies of the enantiomers of warfarin in man. J. Pharm. Pharmacol. 25, 455-465 (1973).
35. R. A. O'Reilly: Studies of the optical enantiomorphs of warfarin in man. Clin. Pharmacol Ther. 16, 348-354 (1974).